Login to Your Account



Cephalon Returns Lupuzor Rights to ImmuPharma

By Nuala Moran
BioWorld International Correspondent

Wednesday, October 26, 2011

LONDON – ImmuPharma plc has pulled out of a $500 million cash deal for Lupuzor, over concerns that the lupus treatment would be beached following the acquisition of its licensee Cephalon Inc., by Teva Pharmaceutical Industries Ltd., which was finalized Oct. 14.

London-based ImmuPharma is now scouting for a new partner for the drug, which is ready for Phase III.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription